SNIPR Biome
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $108.0Mattributed |
|---|---|
| Latest round | series-b, $37.8M, 2025-08-15attributed |
| Founded | 2017 |
| Headquarters | Copenhagen, Denmark |
| Industry | bio |
| Stage | series-b+ |
| Website | snipr.bio |
SNIPR Biome is a Danish clinical-stage biotech developing CRISPR-based precision medicines that selectively kill harmful bacteria, led by SNIPR001 against drug-resistant E. coli. It targets patients at risk of life-threatening infections, like transplant patients. Its edge is microbiome-targeting CRISPR that spares commensal flora.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-08-15 | series-b | $37.8M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $37.8M | attributed | eu-startups named as publisher. No document URL on file. |
| Total raised $108.0M | attributed | eu-startups named as publisher. No document URL on file. |
| Company existence | self-reported | snipr.bio, read 2026-05-07 |
| Description | self-reported | snipr.bio, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.